How Will Healthcare Reform and Payer-Led Cost-Containment Strategies Impact U.S. Prescribing? The market opportunity for hepatitis C virus (HCV) features a large prevalent population, a…
Myelofibrosis (MF), a rare bone marrow disorder, is one of four chronic myeloproliferative neoplasms (MPN) with no curative therapy except for allogeneic hematopoietic stem cell transplantation. MF…
Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs) and is characterized by irreversible loss of lung function leading to high…
Cystic fibrosis (CF) is a genetic disease affecting chloride transport in a variety of tissues, most notably the lungs and pancreas, and is caused by mutations in the cystic fibrosis transmembrane…
The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate the virus from the patient’s body and thereby reduce or halt the progression of liver fibrosis, preventing further…
What Untapped Opportunities Remain for the Treatment of Genotype-3 Infections? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) is a serious public health crisis…
What Untapped Opportunities Remain for the Treatment of Genotype-3 Infections? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) is a serious public health crisis…